Mr. Baroldi is our executive vice president and chief business officer. As a member of the executive leadership team, he is responsible for leading and providing strategic guidance for Ionis’ business development and alliance management activities.

Mr. Baroldi has more than two decades of industry experience. Prior to Ionis, he was chief operating officer at Avidity Biosciences, where he played an integral role in their initial public offering and building their team. Previously, he was vice president, business development at Ionis, where he held several roles of increasing responsibility over 10 years. Before that Mr. Baroldi held positions in strategic planning and scientific research.

Mr. Baroldi holds an M.B.A. from the Rady School of Management at the University of California-San Diego. He received his B.S. in Biological Sciences from the University of California-Irvine.

Mr. Jenne is Ionis’ executive vice president, chief global product strategy officer. He has more than 25 years of biopharmaceutical experience launching and commercializing innovative medicines in the U.S. and globally. He has broad relevant experience in rare, specialty and common diseases across therapeutic areas including cardiovascular, neurology and allergy.

Mr. Jenne leads all aspects of commercialization including marketing, sales, commercial operations, market access and patient services. He also oversees Ionis’ portfolio planning, market insights and medical affairs functions.

Before rejoining Ionis in 2024, Mr. Jenne previously spent five years in senior commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020. During his time at Ionis and Akcea, Mr. Jenne built commercial capabilities in many of Ionis’ key disease areas including transthyretin-mediated amyloidosis and familial chylomicronemia syndrome. Earlier in his career, Mr. Jenne held commercial roles for companies including Schering Plough, King Pharmaceuticals, Acorda Therapeutics and Praecis Pharmaceuticals. Mr. Jenne holds a BS in Marketing from Arizona State University.

Dr. Bennett is the executive vice president and chief scientific officer at Ionis Pharmaceuticals and one of the founding members of the company. He is responsible for continuing to advance Ionis’ technology and expanding the company’s drug discovery platform. Dr. Bennett is also the franchise leader for gene-editing programs at Ionis. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry.

Dr. Bennett has been recognized for his research with numerous awards. He is a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research, the 2021 Gabbay Award and the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA^® (nusinersen), and the inaugural Healy Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS). Dr. Bennett also received the 2018 Hereditary Disease Foundation’s (HDF) Leslie Gehry Brenner Prize for Innovation in Science for his leadership and continued commitment to developing antisense therapies for Huntington’s disease (HD).

Dr. Bennett has published more than 230 papers in the field of antisense research and development, and he is an inventor on more than 175 issued patents.

Prior to joining Ionis, Dr. Bennett was associate senior investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories (currently, GlaxoSmithKline).

He received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. He performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories.

Dr. Bennett serves on the Advisory Board for the Hereditary Disease Foundation and SAB for the McLaughlin Institute.

Ms. Hougen is our executive vice president of Finance and chief financial officer. As a member of our executive leadership team, Ms. Hougen contributes to the execution of our strategy, including ensuring we are well positioned to be a global, multi-product sustainably profitable company. Ionis’ finance, accounting, tax, treasury, information technology, procurement and investor relations functions report to her. Ms. Hougen joined Ionis in May 2000 as vice president, finance, and became chief accounting officer in January 2007 and chief financial officer in January 2013.

Ms. Hougen has an extensive finance and business background having held positions of increasing responsibility in numerous public companies, primarily in the life sciences industry, over her more than 25-year career. Prior to joining Ionis, Ms. Hougen was chief financial officer for Molecular Biosystems, Inc., a public biotechnology company.

In recognition of her important contributions to the financial success of Ionis, in 2018 Ms. Hougen was named a CFO of the Year by the San Diego Business Journal. Ms. Hougen received her M.B.A. from the University of San Diego and her B.A. from Franklin and Marshall College.